Unlocking intra-cellular drug targets

Biotech company devoted to the development of new peptidomimetic drug candidates, obtained through a proprietary platform, able to target undruggable intracellular therapeutic targets. The company has a pipeline centred in schizophrenia, epilepsy, and atherosclerosis. Besides, Iproteos performs partnership agreements with pharmaceutical companies for the co-development of new leads.